Figure 1

Figure 2

Figure 3

PCR primers and annealing temperatures
| Primer name | Primer sequence (5′ → 3′) | Tm (°C) |
|---|---|---|
| Ct.ompA.60UF | GTCCCGCCAGAAAAAGATAG | 45 |
| Ct.ompA.VB3 | CATCGTAGTCAATAGAGGCAT | |
| Ct.ompA.MVF3 | TGTAAAACGACGGCCAGTGCCCGTGCAGCTTTGTGGGAATGT | 45 |
| Ct.ompA.220DR | GCGCTCAAGTAGACCGATATAGTA | |
| F.Ct.trpA | ATTAGCCACCGATGAAGAG | 50 |
| R.Ct.trpA | ATGTTGAATTAGGAGAGTTGTTAT | |
| Ng.opa.F | TTGAAACACCGCCCGGAA | 60 |
| Ng.opa.R | TTTCGGCTCCTTATTCGGTTTAA | |
| Ng.opa.R1 | TTTCGGCTCCTTATTCGGTTTGA | |
| Ng.opa.R2 | TTTCGGCTCCTTATTCGGTTTGA | |
| Ng.porA.F | CAGCATTCAATTTGTTCCGAGTC | 60 |
| Ng.porA.R | GAACTGGTTTCATCTGATTACTTTCCA | |
| PGMY11-A | GCACAGGGACATAACAATGG | 50 |
| PGMY11-B | GCGCAGGGCCACAATAATGG | |
| PGMY11-C | GCACAGGGACATAATAATGG | |
| PGMY11-D | GCCCAGGGCCACAACAATGG | |
| PGMY11-E | GCTCAGGGTTTAAACAATGG | |
| PGMY09-F | CGTCCCAAAGGAAACTGATC | |
| PGMY09-G | CGACCTAAAGGAAACTGATC | |
| PGMY09-H | CGTCCAAAAGGAAACTGATC | |
| PGMY09-I | GCCAAGGGGAAACTGATC | |
| PGMY09-J | CGTCCCAAAGGATACTGATC | |
| PGMY09-K | CGTCCAAGGGGATACTGATC | |
| PGMY09-L | CGACCTAAAGGGAATTGATC | |
| PGMY09-M | CGACCTAGTGGAAATTGATC | |
| PGMY09-N | CGACCAAGGGGATATTGATC | |
| PGMY09-P | GCCCAACGGAAACTGATC | |
| PGMY09-Q | CGACCCAAGGGAAACTGGTC | |
| PGMY09-R | CGTCCTAAAGGAAACTGGTC | |
| HMB01 | GCGACCCAATGCAAATTGGT | |
| globinF | GAAGAGCCAAGGACAGGTAC | 58 |
| globinR | CAACTTCATCCACGTTCACC |
Polymorphisms of C_ trachomatis ompA and trpA among 14 Thai clinical isolates compared with the respective reference serovars
| ompA | trpA | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Reference ompA genotype | Patient name | p-distance±S.E. | nt differences (type and position of changes) | dN/dS dN/dS represents the ratio of non-synonymous (dN) to synonymous (dS) amino acid changes | Serovars that the clinical sequence is most similar to If >1 serovars are most similar to the ompA or trpA sequence of the clinical isolate, the serovars are listed in alphabetical order (A, Ba, C, D, Da, E, F, G, H, I, Ia, J, Ja, K, L1, L2, L2a, L3) and bold for the respective reference serovar. For trpA analysis, serovar Β is excluded because of its lack of trpA | p-distance±S.E. | nt differences (type and position of changes) | dN/dS (type and position of dN changes) | Serovars that the clinical sequence is most similar to |
| D/Ulbf | .000±.000 | 3 (G903A, A927QA937G) Y313C) | 3/0(D301N, S309G | D | .000 ±.000 | 0 | – | D, K | |
| D/U9bf | .000±.000 | 3 (G903A, A927QA937G) | 3/0(D301N, S309G, Y313C) | D | .000 ±.000 | 0 | – | D, K | |
| D | D/U14bf | .006±.003 | 4(C258G, C594T, T601C, G603C) | 0/4 | D | .000 ±.000 | 0 | — | D, K |
| D/Lllbf | .003 ± .002 | 2(C258C, G428C) | 1/1 (S143T) | D | .005 ±.003 | 3(A110G, C344T, G530A) | 3/0(Q37R, A115V, C177Y) | H, Ia, J, Ja | |
| E/U2bf | .000 ±.000 | 0 | – | E | .000 ±.000 | 0 | – | E | |
| E/U4bf | .000 ±.000 | 0 | – | E | .000 ±.000 | 0 | – | E | |
| E | E/U28bf | .000 ±.000 | 0 | – | E | .000 ±.000 | 0 | – | E |
| E/L8bf | .000 ±.000 | 0 | – | E | .000 ±.000 | 0 | – | E | |
| F | F/U29bf | .000 ±.000 | 0 | – | F | .000 ±.000 | 0 | – | F, I |
| F/Llbf | .000 ±.000 | 2(G769C, G775C) | 2/0(R257T, S259T) | F | .000 ±.000 | 0 | – | F, I | |
| G | G/U18bf | .000 ±.000 | 0 | – | G | .002 ±.002 | 1 (C10T) | 0/1 | F, I |
| G/U3M | .000 ±.000 | 0 | – | G | .002 ±.002 | 1 (C10T) | 0/1 | F, I | |
| H/U20bf | .000 ±.000 | 2(G795A, G885A) | 2/0(G265R, W295.) | H | .004 ±.002 | 2(G110A, T344C) | 2/0(R37Q, V115A) | F, I | |
| H | H/L23bf | .000 ±.000 | 4(C270A, A271C, C850T, G885A) | 4/0(N90H, T284I, W295.) | H | .000 ±.000 | 0 | — | H, Ia, J, Ja |
| K | K/U15bf | .000 ±.000 | 0 | – | K | .000 ±.000 | 0 | – | D,K |
C_ trachomatis serovar distribution and infection pattern after doxycycline treatment
| Symptomatic | No. of patients (%) | Doxycycline treatment | |||||
|---|---|---|---|---|---|---|---|
| C. trachomatis | N. gonorrhoeae | HPV | |||||
| Before | After | Before | After | Before | After | ||
| Serovar D | 6 (32) | 6 | 2/4 The number after the solidus (/) represents the number of patients who did not come back after the treatment for C. trachomatis, N. gonorrhoeae, or HPV | 0 | 0 | 3 | 1/2 |
| Serovar E | 4 (21) | 4 | 1/3 | 0 | 0 | 4 | 1/3 |
| Serovar F | 4 (21) | 4 | 1/3 | 1 | 0/1 | 4 | 1/3 |
| Serovar G | 2 (11) | 2 | 0/2 | 0 | 0 | 1 | 0/1 |
| Serovar H | 2 (11) | 2 | 0/2 | 0 | 0 | 1 | 0/1 |
| Serovar K | 1 (5) | 1 | 0/1 | 0 | 0 | 0 | 0 |
Prevalence of STIs in symptomatic and asymptomatic urogenital tract females
| Symptom location Symptom location includes UGT (upper urogenital tract), LGT (lower urogenital tract), Undefined (undefined UGT or LGT), and none for asymptomatic | Ct Ct represents C. trachomatis | Ng Ct represents C. trachomatis | HPV (%) | Characterized by ages (%) | Ct Ng represents N. gonorrhoeae | Ng Ng represents N. gonorrhoeae | HPV (%) | Characterized by occupation (%) | Ct (%) | Ng (%) | HPV (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Symptomatic | |||||||||||
| UGT | 18 | 4 | 35 | 15-24 | 12 (36) | 2 (22) | 18 (25) | Commercial | 1 | 2 | 9 |
| (57) | (12) | (3) | (23) | 25-34 | 5 (15) | 1 (11) | 8 (11) | sex worker | (3) | (22) | (13) |
| 35-44 | 1 (3) | 1 (11) | 6 (8) | ||||||||
| Non-commercial | 17 | 2 | 26 | ||||||||
| 45-54 | 0 | 0 | 1 (1) | sex worker | (52) | (22) | (36) | ||||
| N/A | 0 | 0 | 2 (2) | ||||||||
| LGT | 14 | 5 | 29 | 15-24 | 4 (12) | 0 | 11 (15) | Commercial | 4 | 1 | 10 |
| (75) | (9) | (3) | (19) | 25-34 | 4 (12) | 4 (44) | 11 (15) | sex worker | (12) | (11) | (14) |
| 35-44 | 5 (15) | 0 | 7 (10) | Non-commercial | 10 | 4 | 19 | ||||
| 45-54 | 1 (3) | 1 (11) | 0 | sex worker | (30) | (44) | (26) | ||||
| N/A | 0 | 0 | 0 | ||||||||
| Undefined | 1 | 0 | 8 | 15-24 | 0 | 0 | 1 (1) | Commercial | 1 | 0 | 4 |
| (18) | (1) | (5) | 25-34 | 0 | 0 | 3 (4) | sex worker | (3) | (6) | ||
| 35-44 | 0 | 0 | 0 | Non- | |||||||
| 45-54 | 0 | 0 | 0 | commercial | (6) | ||||||
| N/A | 1 (3) | 0 | 4 (6) | sex worker | |||||||
| Total | 33 | 9 | 72 | 15-24 | 16 (48) | 2 (22) | 30 (42) | Commercial | 6 | 3 | 23 |
| (150) | (22) | (6) | (48) | 25-34 | 9 (27) | 5 (56) | 22 (31) | sex worker | (18) | (33) | (32) |
| 35-44 | 6 (18) | 1 (22) | 13 (18) | Non-commercial | 27 | 6 | 49 | ||||
| 45-54 | 1 (3) | 1 (11) | 1 (1) | sex worker | (82) | (67) | (68) | ||||
| N/A | 1 (3) | 0 | 6 (8) | ||||||||
| Asymptomatic | |||||||||||
| None | 4 | 21 | 14 | 15-24 | 0 | 7 (33) | 6 (43) | Commercial | 3 | 10 | 7 |
| (134) | (3) | (16) | (10) | 25-34 | 4 (100) | 6 (29) | 1 (7) | sex worker | (75) | (47.62) | (50) |
| 35-44 | 0 | 4 (19) | 4 (29) | Non-commercial | 1 | 11 | 7 | ||||
| 45-54 | 0 | 3 (14) | 3 (21) | sex worker | (25) | (52.38) | (50) | ||||
| N/A | 0 | 1 (5) | 0 | ||||||||